These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22712447)

  • 21. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
    Cuker A; Ptashkin B; Konkle BA; Pipe SW; Whinna HC; Zheng XL; Cines DB; Pollak ES
    J Thromb Haemost; 2009 Jan; 7(1):80-6. PubMed ID: 19017257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring heparin therapy: APTT results from partial- vs full-draw tubes.
    Siegel JE; Bernard DW; Swami VK; Sazama K
    Am J Clin Pathol; 1998 Aug; 110(2):184-7. PubMed ID: 9704617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ineffectiveness of a non-weight based heparin regimen in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome.
    Salamonson Y
    Aust Crit Care; 2000 Nov; 13(4):128-33. PubMed ID: 16948203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of aPTT reporting in Canadian medical laboratories. The need for increased standardization. Thrombosis Interest Group of Canada.
    Brigden ML; Johnston M
    Am J Clin Pathol; 2000 Aug; 114(2):276-82. PubMed ID: 10941344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.
    Byun JH; Jang IS; Kim JW; Koh EH
    Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges.
    van den Besselaar AM; Sturk A; Reijnierse GL
    Thromb Res; 2002 Sep; 107(5):235-40. PubMed ID: 12479884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current considerations in the use of the APTT in monitoring unfractionated heparin.
    Nelson DE
    Clin Lab Sci; 1999; 12(6):359-64. PubMed ID: 10724634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standardization of coagulation tests.
    Opartkiattikul N
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
    Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing.
    Pace M; Koury K; Gulur P
    Anesth Analg; 2014 Nov; 119(5):1215-8. PubMed ID: 25225890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.
    Bürki S; Brand B; Escher R; Wuillemin WA; Nagler M
    BMJ Open; 2018 Jun; 8(6):e022943. PubMed ID: 29886450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring of unfractionated heparin in critically ill patients.
    Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S
    Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Monitoring of heparin therapy].
    Camici M; Evangelisti L
    Minerva Med; 1993 Oct; 84(10):507-9. PubMed ID: 8247304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged activated partial thromboplastin time in thromboprophylaxis with unfractionated heparin in patients undergoing cesarean section.
    Matsubara S; Usui R; Ohkuchi A; Okuno S; Izumi A; Watanabe T; Seo N; Suzuki M
    J Obstet Gynaecol Res; 2010 Feb; 36(1):58-63. PubMed ID: 20178528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring heparin anticoagulation in the acute phase response.
    Uprichard J; Manning RA; Laffan MA
    Br J Haematol; 2010 May; 149(4):613-9. PubMed ID: 20230412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.